Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the “SirPAD” randomized controlled trial

[1]  T. Lehmann,et al.  Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: A systematic review and meta-analysis of randomised controlled trials , 2019, EClinicalMedicine.

[2]  K. Rahimi,et al.  Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. , 2019, The Lancet. Global health.

[3]  S. Spiliopoulos,et al.  Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials , 2018, Journal of the American Heart Association.

[4]  R. Hawkins,et al.  Major adverse limb events and major adverse cardiac events after contemporary lower extremity bypass and infrainguinal endovascular intervention in patients with claudication , 2018, Journal of vascular surgery.

[5]  Tracy Y. Wang,et al.  Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization. , 2018, Journal of the American College of Cardiology.

[6]  E. Veen,et al.  Reinterventions after Endovascular Revascularization in Elderly Patients with Critical Limb Ischemia: An Observational Study. , 2018, Annals of vascular surgery.

[7]  Deepak L. Bhatt,et al.  Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. , 2018, Journal of the American College of Cardiology.

[8]  J. Bosch,et al.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.

[9]  Marc P. Bonaca,et al.  Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.

[10]  S. Lewis,et al.  Guidelines for the Content of Statistical Analysis Plans in Clinical Trials , 2017, JAMA.

[11]  J. Mehaffey,et al.  Lower extremity bypass for critical limb ischemia decreases major adverse limb events with equivalent cardiac risk compared with endovascular intervention. , 2017, Journal of vascular surgery.

[12]  A. Wanhainen,et al.  Long-term Outcome after Thrombolysis for Acute Lower Limb Ischaemia. , 2017, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[13]  T. Zeller,et al.  Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease , 2016, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[14]  Zhen Wang,et al.  The natural history of untreated severe or critical limb ischemia. , 2015, Journal of vascular surgery.

[15]  D. Scheinert,et al.  Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.

[16]  G. Tepe,et al.  Drug-Coated Balloon versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and/or Popliteal Peripheral Artery Disease: 12-Month Results From the IN.PACT SFA Randomized Trial , 2015 .

[17]  F. Vermassen,et al.  Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. , 2014, Journal of the American College of Cardiology.

[18]  D. Scheinert,et al.  Nitinol Stent Implantation in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the Complete SE Multicenter Trial , 2014, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[19]  M. Makaroun,et al.  Contemporary outcomes of endovascular interventions for acute limb ischemia. , 2014, Journal of vascular surgery.

[20]  D. Scheinert,et al.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.

[21]  U. Christians,et al.  Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[22]  Raimund Erbel,et al.  [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. , 2012, Revue medicale de Liege.

[23]  M. Dake,et al.  Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results , 2011, Circulation. Cardiovascular interventions.

[24]  F. Neumann,et al.  Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. , 2011, European heart journal.

[25]  R. D'Agostino,et al.  Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.

[26]  K. Ouriel,et al.  A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. , 1998, The New England journal of medicine.